J&J's clinical Dx business draws private equity bidders; Roche/Ventana rolls out new cancer test;

> A number of major private equity firms have reportedly submitted first-round bids for Johnson & Johnson's ($JNJ) Ortho Clinical Diagnostics unit. Story

> Roche's ($RHHBY) Ventana Medical Systems rolled out a new immunohistochemistry test designed to spot the BRAF V600E mutation in a variety of tumors. Item

> Trovagene ($TROV), a San Diego-based molecular diagnostics company, has launched what it bills as the first urine-based cancer mutation monitoring test. Item

> Insight Genetics inked a global licensing deal with St. Jude Children's Research Hospital for a genetic test that helps predict the success of bone marrow transplants by identifying the ideal bone marrow donor subtype. Item    

> Belgium's MDxHealth won reimbursement for its prostate cancer diagnostic test from two major U.S. insurers. Story

> Switzerland's MolecularHealth, a genetics testing company, hired a Texas-based chief medical officer as it makes plans to open its first U.S. office. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.